PASG: Passage Bio, Inc. Company Buyout Price

Passage Bio, Inc. (PASG) is managed by CNS therapy experts who ensure process transparency and rigorous financial oversight. The company relies on a unified technological platform for treating brain pathologies, which creates specific vector safety risks. Market price action reflects an Enterprise Value of -13.35. The business generates revenue through insurance reimbursements for one-time enzyme restoration in rare genetic disorders.

Enterprise value determines the intrinsic price of a business by combining market capitalization with net debt. The enterprise value indicator on the GURU.Markets platform allows for an assessment of the actual costs required for a full buyout of an asset. The formula adjusts the equity value for the volume of borrowed funds and available cash. For Passage Bio, Inc. (PASG), this metric confirms the value of its biomedical facilities. The modernization of ultracentrifugation systems creates a foundation for the long-term growth of the company's value.